KITE-363 is under clinical development by Gilead Sciences and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase II drugs for Chronic Lymphocytic Leukemia (CLL) have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how KITE-363’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KITE-363 overview
KITE-363 is under development for the treatment of relapsed and refractory B-cell lymphoma and diffuse large B-cell lymphoma, mantle cell lymphoma, recurrent chronic lymphocytic leukemia, refractory chronic lymphocytic leukemia, acute lymphocytic leukemia, burkitt lymphoma, primary mediastinal b-cell lymphoma, refractory acute myeloid leukemia. The drug candidate consists of autologous T-cells are engineered to express dual chimeric antigen receptors (CAR) that targets cells expressing CD19 and CD20. It is administered through intravenous route.
Gilead Sciences overview
Gilead Sciences (Gilead) is a research-based biopharmaceutical company. It carries out the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, cancer, and human immunodeficiency virus (HIV) infection. It markets its products through commercial teams, third-party distributors and corporate partners. Gilead’s commercial teams promote its products through direct field contact with physicians, hospitals, clinics and other healthcare providers. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East, and Africa. Gilead is headquartered in Foster City, California, the US.
For a complete picture of KITE-363’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
